Drug design

#AI / data analytics / healthtech / informatics #Drug design #Drug discovery

Virtual drug design platform set to accelerate drug discovery 

The Cambridge Crystallographic Data Centre (CCDC) has entered a strategic partnership with Dassault Systèmes to advance bioscience innovation with a cloud-based virtual screening solution.  The collaboration  The collaboration integrates GOLD — CCDC’s protein-ligand docking software for drug discovery — with Dassault Systèmes’ BIOVIA therapeutics design… Read More

#News

#Cancer immunotherapy #Collaboration #Drug design #Drug targets #Oncology

Collaboration will investigate next-generation cancer therapies 

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.   The agreement  The POLARISqb Tachyon quantum computing platform will be used to scan billions of… Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#AI / data analytics / healthtech / informatics #Drug design

Iktos and Chiesi Group in AI drug design collaboration

Iktos, which specialises in artificial intelligence (AI) for new drug design, is teaming up with Chiesi Group. Under the agreement, Iktos’s de novo generative design software Makya will be used by Chiesi scientists for the design of novel compounds and to accelerate hit-to-lead/lead optimisation. Iktos’ AI technology, based on deep generative models,… Read More

#News

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the most effective healthcare interventions for reducing… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

#AI #AI / data analytics / healthtech / informatics #Drug design #Drug development #Drug discovery

AI round-up: the expanding influence of AI in drug discovery 

Artificial intelligence (AI) is intelligence demonstrated by machines, as opposed to intelligence demonstrated by animals (including humans). According to a report by IDTechEx, the application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. They say the potential for… Read More

#Editor's Choice #Exclusive Content #News

#Drug design #Immunology / Virology & Vaccines #Lipidomics #Lipids #Metabolomics

Lipidomics in biomedical research: chance and challenges

Listen to this article on the DDW Podcast: Lipids are essential for numerous functions in the human body. They are not only components of cell membranes, extracellular vesicles and hormones, but also store energy, facilitate metabolism, mediate cell signalling pathways, and much more. Afrisha Anderson, a Product Manager at Merck KGaA,… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Covid-19 #Drug design #Drug development #Drug discovery

ACRO releases toolkit to help advance decentralised clinical trials

The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs… Read More

#News

#Cannabinoid #Drug design #Drug discovery #Medicinal cannabis #Pharma

Cultivating cannabis for pharmaceuticals: an inside view

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to… Read More

#Business & Investment #Editor's Choice #News #Opinion

#AI #AI / data analytics / healthtech / informatics #Biotherapeutics #Covid-19 #Drug design #Drug development #Therapeutics

Exscientia accelerates Covid-19 drug discovery using AI

Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the Covid-19 Therapeutics Accelerator initiative, to progress a new class of Covid-19 therapeutics created using its artificial intelligence (AI) drug design platform. Exscientia has demonstrated proof-of-concept by using its AI platform… Read More

#News

#Biosciences #Biotherapeutics #Drug design #Drug development #Drug discovery

New approach will help identify drugs that can ‘glue’ proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester. The research paves the way for drug developers to screen large numbers of potential new… Read More

#Editor's Choice #News

#Alzheimer's #Data #Drug delivery #Drug design #Exscientia #Pharma

The role of AI in Alzheimer’s drug candidate design

Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More

#Exclusive Content #News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#Antibodies #Cell therapy #Drug design #Drug technology #Protein Fluidics #Software

Updated platform helps streamline workflows

Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run. Read More

#News

#Clinical trial #Drug design #Drug development #Drug discovery #Research

Call to rethink “primitive” clinical trial approaches

Virtual clinical development specialist, Phesi, is calling for clinical trials to be designed using industry modal values (data values that appear most often in historical trials data) to reduce protocol amendments. Phesi analysed 330,000 clinical trials from the past 15 years and found the majority require substantial protocol amendments and… Read More

#News